Phase I Trial of DS-8201a (Trastuzumab Deruxtecan) in Combination With Neratinib in Solid Tumors With HER2 Alterations
This early-stage study tests how safe it is to combine two targeted cancer drugs, neratinib and trastuzumab deruxtecan. Researchers want to find the best dose of this combination to help shrink solid tumors that have specific gene changes called HER2.
You may be able to join if you have a solid tumor (such as advanced pancreatic cancer or other cancers) that cannot be removed by surgery or has spread, and tests show it has the HER2 gene change. There are rules about recent treatments you may have had, which the study team will review with you.
During the study, you will take the study medications and have regular check-ups, which include imaging scans, heart function tests, and providing small tissue or blood samples for research.
This study is currently recruiting participants and takes place in locations including Duarte and Irvine, California.
- 1Tests a combination of two targeted cancer therapies.
- 2Designed for advanced solid tumors with HER2 gene changes.
- 3Involves regular check-ups, imaging scans, and heart tests.
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.